

TL

JCWSCS 2 4 JUN 2004

06/24/2004 12:02 FAX 1 415 398 3249

DORSEY & WHITNEY LLP-SF

001



FAX COVER SHEET

The information contained in this facsimile message, if a client of this firm is a named addressee, or the message is otherwise intended for a client, is presumptively legally privileged and confidential information. If you are not a named addressee, or if there is any reason to believe that you may have received this message in error, (1) do not read the message below; (2) do not distribute or copy this facsimile; and (3) please immediately call us collect at the number of the sender below.

DATE: **June 24, 2004** TOTAL # OF PAGES: **5**
(INCLUDING THIS COVER SHEET)

TO: **U.S. PATENT AND TRADEMARK OFFICE
OFFICE OF INITIAL PATENT EXAMINATION'S
FILING RECEIPT CORRECTIONS** FAX #: **(703) 746-9195**
PHONE #:

FROM: **David C. Foster, Ph.D.** FAX #: **(415) 398-3249**
PHONE #: **(415) 544-7085** EMAIL: **foster.david@dorsey.com**

COMMENTS:

PLEASE ACKNOWLEDGE RECEIPT BY RETURN FACSIMILE.

ORIGINAL WILL BE SENT VIA: ☐ MAIL ☐ E-MAIL ☐ MESSENGER ☐ AIR COURIER ☒ WILL NOT BE SENT

PLEASE CONTACT MARI KLEINEIDAM AT (415) 544-7065 IF THIS TRANSMISSION IS INCOMPLETE OR CANNOT BE READ.

REFERENCE # A-72186-1/TAL/OCF (471702-00008)

DORSEY & WHITNEY LLP · WWW.DORSEY.COM · T 415.781.1989 · F 415.398.3249
FOUR EMBARCADERO CENTER · SUITE 3400 · SAN FRANCISCO, CALIFORNIA 94111-4187
USA CANADA EUROPE ASIA

Attorney Docket No.: A-72186-1/MJM/TAL/DCF (471702-00008)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re application of:QI, *et al.*

Serial No.: 10/804,763

Filed: March 19, 2004

For: GENE THERAPY VECTORS
HAVING REDUCED
IMMUNOGENICITY

Examiner: Unknown

Group Art Unit: 1645

CERTIFICATE OF FACSIMILE §1.6(d)

I hereby certify that this correspondence, including listed enclosure(s), is being transmitted via facsimile to: Commissioner for Patents, Office of Initial Patent Examination's Filing Receipt Corrections, P.O. Box 1450, Alexandria, VA 22313-1450, facsimile number (703) 746-9195 on:

Dated: June 24, 2004

Signed: Mari Kleineidam
Mari KleineidamREQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination's
Filing Receipt Corrections
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Appended hereto, in support of this request for correction of the error in the filing receipt, is a copy of the Official Filing Receipt, mailed on May 20, 2004 for the above-identified patent application with the error crossed out and marked.

Please change the total number of claims from "17" to -41-.

Applicants do not believe a fee is due in connection with this Request for Corrected Filing Receipt. However, the Commissioner is authorized to charge any fees believed to be due

SF-1145596_1

Serial No.: 10/804,763
Filed: March 19, 2004


to Deposit Account No. 50-2319, referencing our File No. A-72186-1/MJM/TAL/DCF (471702-00008).

Respectfully submitted,

DORSEY & WHITNEY LLP

Dated:

June 24, 2004



David C. Foster

Registration No. 44,685

Customer Service No. 32940
Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989

SP-1145596_1

Gene therapy vectors having reduced immunogenicity

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).